

**Uni-Bio Science Group Ltd.**
聯康生物科技集團有限公司***Uni-Bio Science Group's Chemical Manufacturing Line in Beijing
Passes GMP 2010 Standard**

(Hong Kong, 8 September 2015) **Uni-Bio Science Group Limited** ("Uni-Bio Science" or the "Group;" HKEx code: 690) is pleased to announce that the Group's chemical manufacturing line in Beijing has successfully passed the inspection under "Good Manufacturing Practice (2010 revision)" ("GMP 2010") and received the Certificate of GMP for pharmaceutical products issued by China Food and Drug Administration ("CFDA") on 17 August 2015.

Mr. Kingsley LEUNG, Executive Director of Uni-Bio Science, said, *"Upgrading to the latest GMP manufacturing standard will provide a number of advantages to the Group, including ensuring freedom to operate, improving product quality and upgrading manufacturing capacity, etc. In addition, we believe the upgrade will provide opportunities for the Group to acquire additional drug licenses to strengthen its competitive position in the industry."*

It is a requirement by the CFDA for all industry participants to upgrade their manufacturing facilities to meet the new GMP 2010 standards by the end of 2015. The new standards closely mirror the standards of the European Medicines Agency. Together with the Group's Shenzhen facility, which has already achieved the GMP 2010 certification in 2013, all of the Group's manufacturing lines are new GMP ready. This achievement is an assertion of the Group's strength in producing high quality drugs, ensuring efficacious and safe products for our patients.

- End -

About Uni-Bio Science Group Limited (SEHK: 0690)

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology

Media Enquiries:**Strategic Financial Relations Limited**

Veron Ng Phone: +852 2864 4831
Angelus Lau Phone: +852 2864 4805
Caley Chan Phone: +852 2114 4950
Fax: +852 2527 1196

Email: veron.ng@sprg.com.hk
Email: angelus.lau@sprg.com.hk
Email: caley.chan@sprg.com.hk